ArticleScientific reports2025
Polymer-free β-cyclodextrins and mefenamic acid inclusion complex nanofibers for enhanced drug solubility and biomedical applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrospun nanofibers for gastric cancer: local therapeutics, biomimetic models, and diagnostic interfaces.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, cyclodextrin (CDs) derivatives were used to form mefenamic acid (MFA) supramolecular inclusion complexes (ICs) via a polymer-free electrospinning technique, aiming to improve drug delivery and therapeutic applications. MFA, a non-steroidal anti-inflammatory drug (NSAID), has low water solubility, but its solubility increases when complexed with CDs. Three β-CDs derivatives such as hydroxypropyl β-cyclodextrins (HCN), methyl β-cyclodextrins (MCN), and sulfobutylether β-cyclodextrins (SCN) were used for MFA ICs. Phase solubility studies showed increased MFA solubility with rising amounts of CDs, with stability constants of 337.1, 684.2, and 931.5 M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.